Financial Services · Insurance - Reinsurance · Synthos Deep Dive · 2026-07-03
| Verdict | Hold — systematic Synthos tier |
| Price (2026-07-02) | $371.35 · market cap ~$14.7B |
| Synthos scores (0–10) | Downside Risk 4 · Growth Quality 4 · Exponential Potential 2 |
| Synthos fair value (base case) | ~$390 → +5% · full range $270 (bear) – $500 (bull) |
| Street consensus | $357 (high $377 / low $332; 8 Buy · 14 Hold · 0 Sell → Hold) — context; note it sits BELOW today's price |
| Valuation | 7.6× trailing EPS · ~7× FY26E · ~6× FY27E · 0.98× book · EV/EBITDA 6.6× · 2.2% dividend |
| Exponential Potential | 2/10 · Low — mature Bermuda reinsurer; premiums are shrinking by design, growth is cyclical not secular, no TAM story |
| Technicals | At the 52-wk high ($371), above 50/200-DMA, but RSI 82 = overbought; +8.9% 12-mo lagged SPY +20.6% |
| Conviction | Low — 0 expert voices, 0 claims in the KB; the call rests entirely on fundamentals and quant |
| Position sizing | If owned: small ~1–3% value/ballast sleeve, not a core growth holding |
| Next catalyst | 2026-07-29 Q2'26 earnings (Street EPS $14.25, revenue ~$4.0B) |
| Single biggest risk | A major-catastrophe year (hurricane/quake) plus a repeat of 2024's reserve strengthening |
One-line thesis. Everest is a cheap (7.6× earnings, 0.98× book), low-leverage, A+-rated global reinsurer that just posted a clean quarter (Q1'26 combined ratio 91.2%, 16.7% operating ROE) after a brutal 2024 reserve blowup — but it is a cyclical underwriter shrinking premiums to defend margin, not a growth compounder, so the honest verdict is Watch: own it for value and yield if you want reinsurance ballast, but there is no secular tailwind and the catastrophe tail is real.
Everest is a reinsurance company — it sells insurance to other insurance companies, plus some specialty commercial insurance. When a hurricane or earthquake hits, Everest helps pay the bill; in calm years it keeps the premiums as profit. It is based in Bermuda, it is large ($14.7B), old (founded 1973), and financially very solid (top A+ rating, little debt).
Is the stock cheap or expensive? Cheap. You pay about $7.60 for every $1 of last year's profit (most stocks cost far more), and the whole company trades at roughly the value of its own net worth (book value). Cheap for a reason, though: profits jump around wildly depending on how bad the disaster year is. In 2024 the company had to admit past claims cost more than expected and took a big loss; in early 2026 it bounced back to a strong profit.
Our verdict is Watch — a "keep an eye on it" call, not a "buy now." It's a fine, well-run, cheap business, but it does not grow much over time, and the Wall Street price targets actually sit below today's price.
Here's what our three scores mean in everyday terms:
The one big worry: a severe disaster year (major hurricanes or a quake) on top of another "we under-reserved" surprise like 2024 — that combination is what actually breaks a reinsurer.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 73.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = EG · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Everest Group, Ltd. (NYSE: EG) is a Bermuda-domiciled global reinsurance and insurance underwriter, founded 1973, IPO 1995, renamed from Everest Re Group to Everest Group in July 2023. It writes property, casualty, and specialty reinsurance (treaty and facultative — mortgage, catastrophe, marine, aviation, credit/surety, motor, agriculture, etc.) sold to ceding insurers, plus commercial insurance through wholesale/retail brokers and program administrators. ~3,000 employees. CEO Jim Williamson. Fiscal year ends December 31.
Revenue mix (segments). FMP's product segmentation is stale — it still shows the old two-segment structure (FY2024: Reinsurance $11.4B · Insurance $3.6B · Other $0.2B). As of Q1'26 management has re-cut the business into three reportable segments (per the SEC 8-K earnings release, §9): Reinsurance Treaty, Global Wholesale Specialty, and Legacy (run-off). In Q1'26, Reinsurance Treaty drove essentially all underwriting income ($315M of $316M group pre-tax underwriting income); Global Wholesale Specialty added $23M; Legacy was a −$22M drag. Geographic segmentation was not provided by FMP (seg_geo empty).
The strategic story in one line: "shrink to quality." Group gross written premium fell 18.5% year-over-year in Q1'26 as management deliberately walked away from underpriced casualty and non-cat property, defending the combined ratio rather than chasing top line.
There is no expert coverage for EG in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. No investor, analyst, or operator in our tracked panel has said anything about Everest that we can reconcile to a real claim_id.
Per house standard, we do not fabricate conviction. This verdict is therefore entirely fundamentals- and quant-driven: it rests on the reported financials (FMP), the analyst consensus estimates (FMP), management's own SEC 8-K guidance (half-weighted, §9), and the Synthos scoring framework. Treat the absence of KB breadth as a genuine limitation — where LLY carries 13 net-bullish voices and 251 claims, EG carries zero, which is one reason its conviction rating is Low and its verdict is a cautious Watch rather than a Buy.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Below-average | Cheap (7.6× EPS, 0.98× book), lightly levered (net-debt/EBITDA 0.85×), low beta 0.31, A+ rated — but a catastrophe-exposed cyclical with a fresh memory of the 2024 reserve blowup (Q4'24 net loss −$593M). Valuation floor offsets tail risk → mid-low. |
| Growth Quality | 4 · Mediocre | ROE ~13% TTM is fine, not elite; ROIC ~10%. But revenue is flat-to-down on consensus, GWP is shrinking 18% YoY by design, and earnings are lumpy (EPS $60→$32→$38 across FY23–25). No margin compounding, no moat that widens. |
| Exponential Potential | 2 · Low | Mature Bermuda reinsurer. Growth is cyclical, not secular (rate hardening/softening), the second derivative is negative (premiums contracting), and there is no TAM story or acceleration. A value/yield name, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities; the cases bound the range, and the scores above summarize them. Because reinsurers are valued on book value × ROE more than on an earnings multiple, we anchor primarily to price-to-book and cross-check on P/E.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Benign catastrophe year; the "shrink-to-quality" reset holds combined ratio in the low-90s; ROE sustains ~16–17%; market re-rates toward ~1.2× book on ~$400+ BVPS. FY27E EPS ~$60 at ~8×. | ~$500 (+35%) |
| Base (our anchor) | Normalized catastrophe load; combined ratio mid-90s; ROE ~13–14%; the stock earns roughly ~1.0× book (BVPS ~$390, growing) with EPS ~$52–60 at ~6.5–7×. | ~$390 (+5%) |
| Bear | Heavy catastrophe year and/or another adverse reserve charge like 2024; ROE dips to high-single-digits; multiple de-rates to ~0.7× book. EPS compresses toward ~$30. | ~$270 (−27%) |
Synthos fair value = the base case, ~$390 (+5%), with the full $270–$500 span as the honest range. This anchor sits modestly above the Street's $357 consensus (which itself is below today's $371 price — the Street sees EG as fully-to-slightly-over valued after its run to the 52-week high). The thin upside to base and the below-price Street target are exactly why this is a Watch, not a Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). EG is neither — it is a mature cyclical:
Exponential Potential: Low (2/10). Own EG, if at all, for cheap book value, a ~13% ROE, and capital return — never for a fast multibagger. This honest framing places EG in a value/ballast sleeve, not the growth or "next-exponential" flagship.
On headline multiples EG is cheap: 7.6× trailing EPS, ~7× FY26E, ~6× FY27E, 0.98× book, EV/EBITDA 6.6×, 2.2% dividend, ~19% FCF yield. But "cheap" is the normal state for a catastrophe-exposed cyclical — the market rationally refuses to pay a high multiple on earnings that can swing to a loss in a bad year (see Q4'24). The right lens for a reinsurer is price-to-book against ROE: at ~1.0× book earning ~13–17% ROE, EG is fairly valued, arguably slightly cheap if the low-90s combined ratio proves durable, and expensive if 2024-style reserve risk recurs.
Street targets (context, not our anchor): consensus $357, high $377, low $332 — notably below the current $371 price, with a Hold rating (8 Buy / 14 Hold / 0 Sell). The Street effectively says "fully valued after the run to highs." Our base FV of ~$390 is a touch more constructive (we give some credit to the operating-ROE reset and growing book value) but still implies only ~+5% — thin. The FMP letter grade is A+, reflecting quality (low debt, good ROE, cheap multiple), which is not the same as upside. Not a bargain with a catalyst; a cheap-but-going-nowhere cyclical — hence Watch.
Reinsurance has a weak-to-modest moat: the "product" (capacity) is largely fungible capital, pricing is cyclical, and returns mean-revert. Everest's edges are real but not wide — scale ($44B investment portfolio, global platform), an A+ balance-sheet/rating that lets it write large treaties, underwriting discipline (the shrink-to-quality reset), and a growing specialty/wholesale book. But it competes head-to-head with better-diversified or higher-return peers and is a price-taker in soft markets. The 2024 reserve charge showed the moat does not protect against mis-estimating long-tail casualty risk.
Peer set (market cap, from FMP): RenaissanceRe (RNR) $13.9B — the closest pure-cat-reinsurance comp; Reinsurance Group of America (RGA) $14.5B; Brookfield Wealth Solutions (BNT) $14.4B; MetLife (MET) $57.9B; CNA Financial (CNA) $13.8B; Equitable (EQH) $12.4B; Fidelity National Financial (FNF) $13.1B; Erie Indemnity (ERIE) $12.0B; Banco de Chile (BCH) $19.9B. Against RNR and RGA, EG is mid-pack on ROE and trades at a comparable low book multiple — no valuation dislocation to exploit.
Thesis tripwires (what would change the call): a fresh adverse reserve charge; combined ratio back above 100%; ROE falling into the high-single-digits; or a de-rating below ~0.8× book on a bad-cat year. Conversely, two-plus quarters of low-90s combined ratio and 15%+ ROE with growing book value would upgrade the case toward Buy — Tactical.
Watch. Everest is a genuinely cheap (7.6× EPS, ~1× book), low-leverage, A+-rated global reinsurer that has executed a credible turnaround off the 2024 reserve shock — Q1'26's 91.2% combined ratio and 16.7% operating ROE are real, and capital return is aggressive. But it is a mature, catastrophe-exposed cyclical with shrinking premiums, no moat that compounds, no expert coverage in our KB, and a stock that has run to its 52-week high at an overbought RSI, above the Street's own price target. The honest read is fairly valued with thin upside and a fat tail — that is a Watch, not a Buy.
claim_id citations and the verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and none is asserted here.